[Skip to Content]
[Skip to Content Landing]
Views 822
Citations 0
Invited Commentary
November 2016

Anti–Factor Xa Assay—A Changing Standard for Venous Thromboprophylaxis?

Author Affiliations
  • 1Division of Vascular Surgery, Department of Surgery, Rutgers–New Jersey Medical School, Newark, New Jersey
  • 2Division of Vascular Surgery, Department of Surgery, Hackensack University Medical Center, Hackensack, New Jersey
 

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Surg. 2016;151(11):1014. doi:10.1001/jamasurg.2016.1851

Venous thromboembolism (VTE) represents a significant public health concern and is the leading cause of preventable deaths in hospitalized patients. The Agency for Healthcare Research and Quality has identified this topic as a top 10 public safety concern to be addressed.1 As with other VTE investigations, lower extremity deep vein thrombosis (DVT) serves as a surrogate for fatal pulmonary embolism.

×